RxDoctor Payments Data

Mae Tietje

Primary Care · Atlantic City, NJNPI 1730780479

Payments from drug & device makers

$1,849in general payments, 2019–2025

Across 54 payments — averaging $34.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$495
  • Amgen$378
  • Phathom Pharmaceuticals, Inc.$267
  • Boehringer Ingelheim$212
  • Lilly USA, LLC$137
  • Astellas Pharma US Inc$73
  • plus $286 from 8 others

What the payments were for

  • Food & beverage$1,80498%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,849 in reported general payments places this provider in the 75th percentile of 330 primary care providers in New Jersey.

See all primary care providers in New Jersey

Medicare billing

Part B allowed, 2024
$60,752
Medicare patients
232
Services billed
812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate57$69,638
OzempicSemaglutide49$45,966
FarxigaDapagliflozin Propanediol35$45,837
JardianceEmpagliflozin31$34,864
TradjentaLinagliptin30$28,963
EliquisApixaban22$24,981
Atorvastatin Calcium410$5,233
Breo ElliptaFluticasone/Vilanterol11$3,909
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$3,567
Amlodipine Besylate467$2,958
SymbicortBudesonide/Formoterol Fumarate12$2,834
Albuterol Sulfate HfaAlbuterol Sulfate107$2,391
Fluoxetine Hcl16$2,273
Valsartan53$1,993
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro15$1,959

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$212$63,82761 claims
AstraZenecaFarxiga, Symbicort$495$48,67147 claims
Novo NordiskOzempic$18$45,96649 claims
PfizerEliquis$64$24,98122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 330 primary care providers in New Jersey.

Other primary care in Atlantic City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →